Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.
about
Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic DisordersReview article: pancreatic renin-angiotensin systems in health and diseaseStroke prevention in diabetes and obesityRenin-Angiotensin-aldosterone system in diabetes and hypertensionAngiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records.Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects.The renin angiotensin system and the metabolic syndromeAntihypertensive drugs and glucose metabolismSystematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes.The role of adipose tissue and adipokines in obesity-related inflammatory diseasesThe role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitusManagement of nonalcoholic fatty liver disease: an evidence-based clinical practice review.Captopril normalizes insulin signaling and insulin-regulated substrate metabolism in obese (ob/ob) mouse hearts.Toward integrated and sustainable prevention against diabetes in rural China: study rationale and protocol of eCROPS.Preventing leptin resistance by blocking angiotensin II AT1 receptors in diet-induced obese rats.A systematic review of the role of renin angiotensin aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathyNew onset diabetes after transplantation (NODAT): an overview.Novel views on new-onset diabetes after transplantation: development, prevention and treatment.Physician adherence to hypertension treatment guidelines and drug acquisition costs of antihypertensive drugs at the cardiac clinic: a pilot study.Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin.Advances in the treatment of prediabetes.The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy.Impact of Angiotensin Converting Enzyme Inhibitor versus Angiotensin Receptor Blocker on Incidence of New-Onset Diabetes Mellitus in Asians.Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence.Therapeutic potential of angiotensin receptor blockers in hypertension.The burden of type 2 diabetes: strategies to prevent or delay onsetEffective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartan.Angiotensin-Converting Enzyme 2 Deficiency Aggravates Glucose Intolerance via Impairment of Islet Microvascular Density in Mice with High-Fat Diet.The role of angiotensin II type 1 receptor blockers in the prevention and management of diabetes mellitus.Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes.Strategies for preventing type 2 diabetes: an update for clinicians.The frail renin-angiotensin system.The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection.Antioxidant effect of angiotensin (1‑7) in the protection of pancreatic β cell function.Prevention of diabetes in hypertensive patients: results and implications from the VALUE trialThe effect of angiotensin-converting enzyme inhibition using captopril on energy balance and glucose homeostasis.Improved Glucose-Stimulated Insulin Secretion by Selective Intraislet Inhibition of Angiotensin II Type 1 Receptor Expression in Isolated Islets of db/db Mice.Complementary mechanisms of angiotensin receptor blockers and calcium channel blockers in managing hypertension.
P2860
Q26740443-FF91BBE6-13B7-48BA-8E30-6625532F5FBBQ26821967-8FF6F37E-2C8E-42CB-AB5B-1E05664252FCQ28200179-69BBD675-2C1B-4866-A5BC-2F82CCC45E85Q28308222-C5187B80-2DA5-4CDC-AF62-D9D9E96B74D3Q31131489-DF475613-2D20-46D9-8602-C0016471E282Q33403831-4512967C-4D4E-45B5-A6BC-D3EF65903420Q33561456-4D2B0AF9-78B0-4462-A667-4C21E495143DQ33915412-1A13C808-9089-4D85-A72A-3ECFD5BC7C9FQ33948469-D43A82E7-13B9-413B-A18A-82936829C732Q33994970-8618C035-F1B7-4E7B-B41C-60C8CEC346AFQ34022211-471EBEDE-513E-4643-B959-F36B22405626Q34127409-42EE2B7A-179D-4D99-B3FA-C34D34A66FDFQ34168532-CF2180E6-BF2B-40F1-839F-3CE13C7F0C3DQ34591369-AEBD5284-C8FC-4DB7-9BB5-292D8BDDE906Q34898480-AB1361F0-1884-40E2-930E-F2CCDB45E775Q34994537-9727B7EC-5968-4A56-92C0-DFD8F8EBB668Q35025285-102BBA3D-E925-432A-BA5C-B69DAA4683A5Q35092351-4621EC2D-9BF3-4265-84C0-89DEC14BF7DBQ35221336-D73F5E37-D0F1-4BD6-9016-58CA9DBC043CQ35751783-5047D113-D654-499F-807F-EA4A561F3838Q36302833-776AA284-3F4E-4AFC-BD7F-61035FBE24BCQ36326017-D42538FB-AE45-4491-BE04-1136ECF7EC4CQ36327944-9B1F9F3D-613D-4C7A-BD25-C4A2DC4DFE1EQ36362376-1B20D3C5-CCB6-40F0-BE09-BF22E678BDBCQ36418694-24371B43-2C3A-4F3A-8903-46A4ACD07CC0Q36480076-ABF09BE5-589B-487E-96E2-035FC8EDB854Q36491825-36C61C16-CC0C-491D-A243-893E57B52723Q36536251-8DC63BD3-30FA-407E-B5D6-1F4F1B035B6DQ36642651-321952C1-14C3-4224-B4D9-35C017D39DFAQ36825669-87AD6BE9-B5BD-4C0F-95A3-EC5449742C7CQ36909521-673CA9CB-B6F8-41EF-8970-733F9A129865Q37076468-BD8FBDEC-6EAA-4622-814F-11412778B6A9Q37117608-03D8B7A4-87C2-46B0-AB5C-05E9254960E0Q37150747-6A90CE3F-E466-4C33-9E3C-9592C90F4FDDQ37169716-BBBA783A-5A04-49C5-A800-5A5B5BBA2FB5Q37190951-6ADA8A5D-997A-40A9-8204-1C4E0BB33746Q37202131-BD3985DD-D1D9-4C7A-A4AE-490FB2D89CD6Q37328877-640B3D94-B843-4955-8C11-8043ADCA90B2Q37382980-2E50DFBE-13DD-4C41-9CCC-444EAC7DD753Q37427235-1BCF2F11-7880-4615-8E86-AA25E3C67359
P2860
Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Renin-angiotensin system inhib ...... of randomised clinical trials.
@ast
Renin-angiotensin system inhib ...... of randomised clinical trials.
@en
type
label
Renin-angiotensin system inhib ...... of randomised clinical trials.
@ast
Renin-angiotensin system inhib ...... of randomised clinical trials.
@en
prefLabel
Renin-angiotensin system inhib ...... of randomised clinical trials.
@ast
Renin-angiotensin system inhib ...... of randomised clinical trials.
@en
P1476
Renin-angiotensin system inhib ...... of randomised clinical trials.
@en
P2093
P304
P356
10.1016/S1262-3636(07)70146-5
P577
2004-12-01T00:00:00Z